{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:21:12Z","timestamp":1789122072541,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Androgen deprivation therapy (ADT) in patients with prostate cancer can have several debilitating side effects. Supervised exercise is recommended to ameliorate these negative effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To systematically evaluate the effect of supervised exercise therapy compared to no exercise therapy in patients with prostate cancer undergoing ADT, primarily according to the patient critical outcomes, \u2018disease-specific quality of life\u2019 and \u2018walking performance\u2019 measured at end of treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched PubMed\/Medline, Embase, Cochrane Library, Cinahl and Pedro, to identify randomised controlled trials (RCTs), which investigated the effect of supervised exercise therapy compared to no exercise therapy in patients with prostate cancer receiving ADT, last search: June 2021. Two independent reviewers extracted data, and assessed risk of bias using Cochrane Risk of Bias Tool and evaluated the certainty of evidence using the GRADE-method.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eigthteen RCTs (<jats:italic>n<\/jats:italic>\u2009=\u20091477) comprised patients with prostate cancer stages T1-T4 were included in the meta-analyses. Compared to no exercise therapy, supervised exercise therapy showed clinically relevant improvements in \u2018disease-specific quality of life\u2019 and \u2018walking performance\u2019. The standardised mean differences were 0.43 (95% confidence interval (CI): 0.29, 0.58) and \u22120.41 (95% CI: \u22120.60, \u22120.22), respectively. The overall certainty of evidence was moderate due to serious risk of bias.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Evidence of moderate quality shows that supervised exercise therapy probably is superior to no exercise therapy in improving \u2018disease-specific quality of life\u2019 and \u2018walking performance\u2019 in patients with prostate cancer undergoing ADT. The results apply to all patients receiving androgen deprivation therapy regardless of cancer stage. The results support a strong recommendation for supervised exercise therapy for managing side effects in this population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Protocol registration<\/jats:title>\n                <jats:p>NKR-38-Focused-questions-PICOs-for-updating1.ashx (sst.dk)<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41391-021-00450-0","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T15:02:53Z","timestamp":1630940573000},"page":"491-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Supervised exercise therapy compared with no exercise therapy to reverse debilitating effects of androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7095-7623","authenticated-orcid":false,"given":"Anja","family":"Ussing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-6593","authenticated-orcid":false,"given":"Marie-Louise Kirkegaard","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0217-4031","authenticated-orcid":false,"given":"Brigitta Rasmussen","family":"Villumsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Wejlgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille Envold","family":"Bistrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2720-5845","authenticated-orcid":false,"given":"Kirsten","family":"Birkefoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bandholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"key":"450_CR1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"450_CR2","first-page":"293","volume":"1","author":"C Huggins","year":"1941","unstructured":"Huggins C, Hodges CV. Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate. Cancer Res. 1941;1:293.","journal-title":"Cancer Res"},{"key":"450_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","volume":"22","author":"ED Crawford","year":"2019","unstructured":"Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019;22:24\u201338.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"450_CR4","unstructured":"Mottet N, Cornford P, van den Bergh R, Briers E, De Santis M & Fanti Sea. EAU - EANM - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer (European Association of Urology (EAU), 2020)."},{"key":"450_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.eururo.2011.08.026","volume":"61","author":"V Pagliarulo","year":"2012","unstructured":"Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schr\u00f6der FH, Sternberg CN, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol. 2012;61:11\u201325.","journal-title":"Eur Urol"},{"key":"450_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","volume":"387","author":"G Attard","year":"2016","unstructured":"Attard G, Parker C, Eeles RA, Schr\u00f6der F, Tomlins SA, Tannock I, et al. Prostate cancer. Lancet. 2016;387:70\u201382.","journal-title":"Lancet"},{"key":"450_CR7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.urolonc.2009.09.004","volume":"29","author":"SM Gilbert","year":"2011","unstructured":"Gilbert SM, Kuo YF, Shahinian VB. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol. 2011;29:647\u201353.","journal-title":"Urol Oncol"},{"key":"450_CR8","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00520-019-05255-5","volume":"28","author":"K Edmunds","year":"2020","unstructured":"Edmunds K, Tuffaha H, Galv\u00e3o DA, Scuffham P, Newton RU. Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review. Support Care Cancer. 2020;28:2079\u201393.","journal-title":"Support Care Cancer"},{"key":"450_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen PL, Alibhai SM, Basaria S, D\u2019Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825\u201336.","journal-title":"Eur Urol"},{"key":"450_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40798-020-0242-8","volume":"6","author":"T Lam","year":"2020","unstructured":"Lam T, Birzniece V, McLean M, Gurney H, Hayden A, Cheema BS. The adverse effects of androgen deprivation therapy in prostate cancer and the benefits and potential anti-oncogenic mechanisms of progressive resistance training. Sports Med Open. 2020;6:13.","journal-title":"Sports Med Open"},{"key":"450_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/aja.2011.104","volume":"14","author":"TW Storer","year":"2012","unstructured":"Storer TW, Miciek R, Travison TG. Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J Androl. 2012;14:204\u201321.","journal-title":"Asian J Androl"},{"key":"450_CR12","first-page":"144","volume":"70","author":"M Tucci","year":"2018","unstructured":"Tucci M, Leone G, Buttigliero C, Zichi C, DI Stefano RF, Pignataro D, et al. Hormonal treatment and quality of life of prostate cancer patients: new evidence. Minerva Urol Nefrol. 2018;70:144\u201351.","journal-title":"Minerva Urol Nefrol"},{"key":"450_CR13","doi-asserted-by":"publisher","first-page":"664.e1","DOI":"10.1016\/j.urolonc.2017.07.016","volume":"35","author":"KT Nead","year":"2017","unstructured":"Nead KT, Sinha S, Yang DD, Nguyen PL. Association of androgen deprivation therapy and depression in the treatment of prostate cancer: a systematic review and meta-analysis. Urol Oncol. 2017;35:664.e1\u2013664.e9.","journal-title":"Urol Oncol"},{"key":"450_CR14","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.euf.2020.05.014","volume":"6","author":"AL Siebert","year":"2020","unstructured":"Siebert AL, Lapping-Carr L, Morgans AK. Neuropsychiatric impact of androgen deprivation therapy in patients with prostate cancer: current evidence and recommendations for the clinician. Eur Urol Focus. 2020;6:1170\u20139.","journal-title":"Eur Urol Focus"},{"key":"450_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/pcan.2016.69","volume":"20","author":"PJ Owen","year":"2017","unstructured":"Owen PJ, Daly RM, Livingston PM, Fraser SF. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. Prostate Cancer Prostatic Dis. 2017;20:137\u201345.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"450_CR16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.eururo.2015.10.047","volume":"69","author":"L Bourke","year":"2016","unstructured":"Bourke L, Smith D, Steed L, Hooper R, Carter A, Catto J, et al. Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016;69:693\u2013703.","journal-title":"Eur Urol"},{"key":"450_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/JCO.2007.15.4963","volume":"27","author":"RJ Segal","year":"2009","unstructured":"Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud\u2019Homme DG, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009;27:344\u201351.","journal-title":"J Clin Oncol"},{"key":"450_CR18","first-page":"25","volume":"127","author":"K Hojan","year":"2017","unstructured":"Hojan K, Kwiatkowska-Borowczyk E, Leporowska E, Milecki P. Inflammation, cardiometabolic markers, and functional changes in men with prostate cancer. A randomized controlled trial of a 12-month exercise program. Pol Arch Intern Med. 2017;127:25\u201335.","journal-title":"Pol Arch Intern Med"},{"key":"450_CR19","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.3109\/0284186X.2015.1037008","volume":"54","author":"TS Nilsen","year":"2015","unstructured":"Nilsen TS, Raastad T, Skovlund E, Courneya KS, Langberg CW, Lilleby W, et al. Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy. Acta Oncol. 2015;54:1805\u201313.","journal-title":"Acta Oncol"},{"key":"450_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/abm\/kax002","volume":"52","author":"BC Focht","year":"2018","unstructured":"Focht BC, Lucas AR, Grainger E, Simpson C, Fairman CM, Thomas-Ahner JM, et al. Effects of a group-mediated exercise and dietary intervention in the treatment of prostate cancer patients undergoing androgen deprivation therapy: results from the IDEA-P trial. Ann Behav Med. 2018;52:412\u201328.","journal-title":"Ann Behav Med"},{"key":"450_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41391-019-0200-z","volume":"23","author":"RU Newton","year":"2020","unstructured":"Newton RU, Galv\u00e3o DA, Spry N, Joseph D, Chambers SK, Gardiner RA, et al. Timing of exercise for muscle strength and physical function in men initiating ADT for prostate cancer. Prostate Cancer Prostatic Dis. 2020;23:457\u201364.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"450_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/bju.14505","volume":"123","author":"DR Taaffe","year":"2019","unstructured":"Taaffe DR, Galv\u00e3o DA, Spry N, Joseph D, Chambers SK, Gardiner RA, et al. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition. BJU Int. 2019;123:261\u20139.","journal-title":"BJU Int"},{"key":"450_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3389\/fphys.2019.00843","volume":"10","author":"Z Chen","year":"2019","unstructured":"Chen Z, Zhang Y, Lu C, Zeng H, Schumann M, Cheng S. Supervised physical training enhances muscle strength but not muscle mass in prostate cancer patients undergoing androgen deprivation therapy: a systematic review and meta-analysis. Front Physiol. 2019;10:843.","journal-title":"Front Physiol"},{"key":"450_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1530\/ERC-15-0456","volume":"23","author":"L Teleni","year":"2016","unstructured":"Teleni L, Chan RJ, Chan A, Isenring EA, Vela I, Inder WJ, et al. Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials. Endocr Relat Cancer. 2016;23:101\u201312.","journal-title":"Endocr Relat Cancer"},{"key":"450_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.24920\/J1001-9242.2007.002","volume":"32","author":"B Yang","year":"2017","unstructured":"Yang B, Wang J. Effects of exercise on cancer-related fatigue and quality of life in prostate cancer patients undergoing androgen deprivation therapy: a meta-analysis of randomized clinical trials. Chin Med Sci J. 2017;32:13\u201321.","journal-title":"Chin Med Sci J"},{"key":"450_CR26","doi-asserted-by":"publisher","first-page":"e7368","DOI":"10.1097\/MD.0000000000007368","volume":"96","author":"G Yunfeng","year":"2017","unstructured":"Yunfeng G, Weiyang H, Xueyang H, Yilong H, Xin G. Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy: An update meta-analysis. Med (Baltim). 2017;96:e7368.","journal-title":"Med (Baltim)"},{"key":"450_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40279-018-1031-0","volume":"49","author":"ED Bjerre","year":"2019","unstructured":"Bjerre ED, Brasso K, J\u00f8rgensen AB, Petersen TH, Eriksen AR, Tolver A, et al. Football compared with usual care in men with prostate cancer (fc prostate community trial): a pragmatic multicentre randomized controlled trial. Sports Med. 2019;49:145\u201358.","journal-title":"Sports Med"},{"key":"450_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4306-9","volume":"18","author":"JK Dawson","year":"2018","unstructured":"Dawson JK, Dorff TB, Todd Schroeder E, Lane CJ, Gross ME, Dieli-Conwright CM. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial. BMC Cancer. 2018;18:368.","journal-title":"BMC Cancer"},{"key":"450_CR29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1249\/MSS.0000000000001454","volume":"50","author":"DA Galv\u00e3o","year":"2018","unstructured":"Galv\u00e3o DA, Taaffe DR, Spry N, Cormie P, Joseph D, Chambers SK, et al. Exercise preserves physical function in prostate cancer patients with bone metastases. Med Sci Sports Exerc. 2018;50:393\u20139.","journal-title":"Med Sci Sports Exerc"},{"key":"450_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/bju.14922","volume":"125","author":"W Ndjavera","year":"2020","unstructured":"Ndjavera W, Orange ST, O\u2019Doherty AF, Leicht AS, Rochester M, Mills R, et al. Exercise-induced attenuation of treatment side-effects in patients with newly diagnosed prostate cancer beginning androgen-deprivation therapy: a randomised controlled trial. BJU Int. 2020;125:28\u201337.","journal-title":"BJU Int"},{"key":"450_CR31","doi-asserted-by":"publisher","unstructured":"Via JD, Owen PJ, Daly RM, Mundell NL, Livingston PM, Rantalainen T et al. Musculoskeletal responses to exercise plus nutrition in men with prostate cancer on androgen deprivation: a 12-month RCT. Med Sci Sports Exerc (2021). https:\/\/doi.org\/10.1249\/MSS.0000000000002682.","DOI":"10.1249\/MSS.0000000000002682"},{"key":"450_CR32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383\u201394.","journal-title":"J Clin Epidemiol"},{"key":"450_CR33","first-page":"395","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing Quest deciding important outcomes J Clin Epidemiol. 2011;64:395\u2013400.","journal-title":"Framing Quest deciding important outcomes J Clin Epidemiol"},{"key":"450_CR34","doi-asserted-by":"crossref","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020) (Cochrane Collaboration, 2020)","DOI":"10.1002\/9781119536604"},{"key":"450_CR35","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sch\u00fcnemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380\u20132.","journal-title":"J Clin Epidemiol"},{"key":"450_CR36","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. & PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"450_CR37","unstructured":"National klinisk retningslinje for rehabilitering af patienter med prostatakr\u00e6ft (Sundhedsstyrelsen, 2021)"},{"key":"450_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12630-008-9007-4","volume":"56","author":"L Thabane","year":"2009","unstructured":"Thabane L, Thomas T, Ye C, Paul J. Posing the research question: not so simple. Can J Anaesth. 2009;56:71\u201379.","journal-title":"Can J Anaesth"},{"key":"450_CR39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1524-4733.2008.00409.x","volume":"12","author":"D Cella","year":"2009","unstructured":"Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy-Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health. 2009;12:124\u20139.","journal-title":"Value Health"},{"key":"450_CR40","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s12603-009-0104-z","volume":"13","author":"S Kwon","year":"2009","unstructured":"Kwon S, Perera S, Pahor M, Katula JA, King AC, Groessl EJ, et al. What is a meaningful change in physical performance? Findings from a clinical trial in older adults (the LIFE-P study). J Nutr Health Aging. 2009;13:538\u201344.","journal-title":"J Nutr Health Aging"},{"key":"450_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-7-10","volume":"7","author":"BJ Shea","year":"2007","unstructured":"Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10.","journal-title":"BMC Med Res Methodol"},{"key":"450_CR42","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"450_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rat Qual Evid J Clin Epidemiol. 2011;64:401\u20136.","journal-title":"Rat Qual Evid J Clin Epidemiol"},{"key":"450_CR44","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/jrsm.46","volume":"2","author":"K Thorlund","year":"2011","unstructured":"Thorlund K, Walter SD, Johnston BC, Furukawa TA, Guyatt GH. Pooling health-related quality of life outcomes in meta-analysis-a tutorial and review of methods for enhancing interpretability. Res Synth Methods. 2011;2:188\u2013203.","journal-title":"Res Synth Methods"},{"key":"450_CR45","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.eururo.2013.09.040","volume":"65","author":"L Bourke","year":"2014","unstructured":"Bourke L, Gilbert S, Hooper R, Steed LA, Joshi M, Catto JW, et al. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol. 2014;65:865\u201372.","journal-title":"Eur Urol"},{"key":"450_CR46","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bju.12646","volume":"115","author":"P Cormie","year":"2015","unstructured":"Cormie P, Galv\u00e3o DA, Spry N, Joseph D, Chee R, Taaffe DR, et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int. 2015;115:256\u201366.","journal-title":"BJU Int"},{"key":"450_CR47","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1200\/JCO.2009.23.2488","volume":"28","author":"DA Galv\u00e3o","year":"2010","unstructured":"Galv\u00e3o DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 2010;28:340\u20137.","journal-title":"J Clin Oncol"},{"key":"450_CR48","doi-asserted-by":"publisher","first-page":"VIII623","DOI":"10.1093\/annonc\/mdy300.064","volume":"29","author":"MR Harrison","year":"2018","unstructured":"Harrison MR, Davis PG, Khouri MG, Gupta RT, Armstrong AJ, McNamara MA, et al. EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naive prostate cancer (HSPC). Ann Oncol. 2018;29:VIII623\u2013VIII624.","journal-title":"Ann Oncol"},{"key":"450_CR49","first-page":"489","volume":"52","author":"K Hojan","year":"2016","unstructured":"Hojan K, Kwiatkowska-Borowczyk E, Leporowska E, G\u00f3recki M, Ozga-Majchrzak O, Milecki T, et al. Physical exercise for functional capacity, blood immune function, fatigue, and quality of life in high-risk prostate cancer patients during radiotherapy: a prospective, randomized clinical study. Eur J Phys Rehabil Med. 2016;52:489\u2013501.","journal-title":"Eur J Phys Rehabil Med"},{"key":"450_CR50","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1249\/MSS.0000000000001831","volume":"51","author":"RU Newton","year":"2019","unstructured":"Newton RU, Galv\u00e3o DA, Spry N, Joseph D, Chambers SK, Gardiner RA, et al. Exercise mode specificity for preserving spine and hip bone mineral density in prostate cancer patients. Med Sci Sports Exerc. 2019;51:607\u201314.","journal-title":"Med Sci Sports Exerc"},{"key":"450_CR51","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1200\/JCO.2003.09.534","volume":"21","author":"RJ Segal","year":"2003","unstructured":"Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003;21:1653\u20139.","journal-title":"J Clin Oncol"},{"key":"450_CR52","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.eururo.2017.02.019","volume":"72","author":"DR Taaffe","year":"2017","unstructured":"Taaffe DR, Newton RU, Spry N, Joseph D, Chambers SK, Gardiner RA, et al. Effects of different exercise modalities on fatigue in prostate cancer patients undergoing androgen deprivation therapy: a year-long randomised controlled trial. Eur Urol. 2017;72:293\u20139.","journal-title":"Eur Urol"},{"key":"450_CR53","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/sms.12260","volume":"24","author":"J Uth","year":"2014","unstructured":"Uth J, Hornstrup T, Schmidt JF, Christensen JF, Frandsen C, Christensen KB, et al. Football training improves lean body mass in men with prostate cancer undergoing androgen deprivation therapy. Scand J Med Sci Sports. 2014;24:105\u201312.","journal-title":"Scand J Med Sci Sports"},{"key":"450_CR54","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1249\/MSS.0000000000001277","volume":"49","author":"BA Wall","year":"2017","unstructured":"Wall BA, GALV\u00e3O DA, Fatehee N, Taaffe DR, Spry N, Joseph D, et al. Exercise Improves V\u02d9O2max and Body Composition in Androgen Deprivation Therapy-treated Prostate Cancer Patients. Med Sci Sports Exerc. 2017;49:1503\u201310.","journal-title":"Med Sci Sports Exerc"},{"key":"450_CR55","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1249\/MSS.0000000000000265","volume":"46","author":"KM Winters-Stone","year":"2014","unstructured":"Winters-Stone KM, Dobek JC, Bennett JA, Maddalozzo GF, Ryan CW, Beer TM. Skeletal response to resistance and impact training in prostate cancer survivors. Med Sci Sports Exerc. 2014;46:1482\u20138.","journal-title":"Med Sci Sports Exerc"},{"key":"450_CR56","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.apmr.2014.08.010","volume":"96","author":"KM Winters-Stone","year":"2015","unstructured":"Winters-Stone KM, Dobek JC, Bennett JA, Dieckmann NF, Maddalozzo GF, Ryan CW, et al. Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial. Arch Phys Med Rehabil. 2015;96:7\u201314.","journal-title":"Arch Phys Med Rehabil"},{"key":"450_CR57","doi-asserted-by":"publisher","unstructured":"Galv\u00e3o DA, Newton RU, Chambers SK, Spry N, Joseph D, Gardiner RA et al. Psychological distress in men with prostate cancer undertaking androgen deprivation therapy: modifying effects of exercise from a year-long randomized controlled trial. Prostate Cancer Prostatic Dis. (2021). https:\/\/doi.org\/10.1038\/s41391-021-00327-2.","DOI":"10.1038\/s41391-021-00327-2"},{"key":"450_CR58","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.prro.2021.01.005","volume":"11","author":"O Schumacher","year":"2021","unstructured":"Schumacher O, Galv\u00e3o DA, Taaffe DR, Spry N, Joseph D, Tang C, et al. Effect of exercise adjunct to radiation and androgen deprivation therapy on patient-reported treatment toxicity in men with prostate cancer: a secondary analysis of 2 randomized controlled trials. Pr Radiat Oncol. 2021;11:215\u201325.","journal-title":"Pr Radiat Oncol"},{"key":"450_CR59","unstructured":"Rehabilitation Measures Database. 30 Second Sit to Stand Test. May 20, 2013. https:\/\/www.sralab.org\/rehabilitation-measures\/30-second-sit-stand-test."},{"key":"450_CR60","doi-asserted-by":"publisher","unstructured":"Lopez P, Taaffe DR, Newton RU, Buffart LM & Galv\u00e3o DA What is the minimal dose for resistance exercise effectiveness in prostate cancer patients? Systematic review and meta-analysis on patient-reported outcomes. Prostate Cancer Prostatic Dis. (2020). https:\/\/doi.org\/10.1038\/s41391-020-00301-4.","DOI":"10.1038\/s41391-020-00301-4"},{"key":"450_CR61","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.euf.2016.02.011","volume":"2","author":"V Vashistha","year":"2016","unstructured":"Vashistha V, Singh B, Kaur S, Prokop LJ, Kaushik D. The effects of exercise on fatigue, quality of life, and psychological function for men with prostate cancer: systematic review and meta-analyses. Eur Urol Focus. 2016;2:284\u201395.","journal-title":"Eur Urol Focus"},{"key":"450_CR62","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1007\/s00520-017-3771-z","volume":"25","author":"M Keilani","year":"2017","unstructured":"Keilani M, Hasenoehrl T, Baumann L, Ristl R, Schwarz M, Marhold M, et al. Effects of resistance exercise in prostate cancer patients: a meta-analysis. Support Care Cancer. 2017;25:2953\u201368.","journal-title":"Support Care Cancer"},{"key":"450_CR63","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3322\/caac.21186","volume":"63","author":"JK Silver","year":"2013","unstructured":"Silver JK, Baima J, Mayer RS. Impairment-driven cancer rehabilitation: an essential component of quality care and survivorship. CA Cancer J Clin. 2013;63:295\u2013317.","journal-title":"CA Cancer J Clin"},{"key":"450_CR64","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1002\/cncr.29672","volume":"121","author":"KA Donovan","year":"2015","unstructured":"Donovan KA, Walker LM, Wassersug RJ, Thompson LM, Robinson JW. Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. Cancer. 2015;121:4286\u201399.","journal-title":"Cancer"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-021-00450-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-021-00450-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-021-00450-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T14:07:05Z","timestamp":1660745225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-021-00450-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["450"],"URL":"https:\/\/doi.org\/10.1038\/s41391-021-00450-0","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]},"assertion":[{"value":"27 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AU and MLK are employed by the Danish Health Authority who initiated and financed the conduction. AU was employed by the Parker Institute at the initiation of the study. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}